Optinose announced peer-reviewed publication of results from both ReOpen and ReOpen2 in the Journal of Allergy and Clinical Immunology: In Practice. The ReOpen program evaluated XHANCE for treatment of adults with chronic sinusitis (chronic rhinosinusitis). Chronic sinusitis is also common: data suggests it is one of the top diagnoses in adult outpatient physician visits.

Although surgery is available, there has never been a medication approved by the FDA as safe and effective for this disease. The primary endpoints include a composite symptom score (congestion, facial pain or pressure, and nasal discharge) and CT scans of the sinuses to objectively measure change in inflammation inside the sinus cavities. In additional statistically well-controlled measures, these trials also showed that XHANCE reduced the incidence of acute disease exacerbations by more than half and that treatment significantly reduced symptoms even for patients who entered the trials with symptoms despite using a standard-delivery nasal spray steroid, which are now generally available at prescription strength as over-the-counter treatments.

The safety profile and tolerability of XHANCE for patients in the ReOpen trials was generally consistent with its currently labeled safety profile.